Viking Therapeutics (NASDAQ: VKTX): The Last Independent Metabolic Challenger

From Clinical Contender to Commercial Platform or a Multi-Billion-Dollar Takeout

AT Investment Research, The M&A Hunter, and Biotech Distilled

Dec 18, 2025

∙ Paid

Forwords from the Alpha Talon Team

This report represents a collaborative effort between Alpha Talon Investment Research, The M&A Hunter, and HalfBakedInnovation. Each contributor brings a distinct lens to the analysis: fundamental valuation, strategic M&A dynamics, and pipeline-clinical driven insights, resulting in a more complete and rigorous assessme…

Continue reading this post for free, courtesy of AT Investment Research.

Or purchase a paid subscription.

A guest post by

The M&A Hunter

Tracking biotech & Banking acquisition targets Featuring acquisition targets with detailed analysis M&A probability signals and catalysts Valuation insight and deal timing estimates Big pharma strategy patterns "NOT Pro Advice"

A guest post by

Biotech Distilled

PhD in Medicinal Chemistry. Extensive experience evaluating drug discovery programs — from molecular mechanism to clinical plausibility.